Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.

导出 LinkOut

翻译打印收藏纠错

作者： Massimo,Breccia ^[1] ; Alessandro,Andriani ^[2] ; Marco,Montanaro ^[3] ; Elisabetta,Abruzzese ^[4] ; Francesco,Buccisano ^[5] ; Michele,Cedrone ^[6] ; Antonietta,Centra ^[7] ; Nicoletta,Villivà ^[8] ; Francesca,Celesti ^[3] ; Malgorzata Monica,Trawinska ^[4] ; Fulvio,Massaro ^[5] ; Ambra,Di Veroli ^[9] ; Barbara,Anaclerico ^[6] ; Gioia,Colafigli ^[7] ; Matteo,Molica ^[9] ; Antonio,Spadea ^[9] ; Luca,Petriccione ^[10] ; Giuseppe,Cimino ^[11] ; Roberto,Latagliata ^[8]

作者单位： Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161, Rome, Italy. breccia@bce.uniroma1.it. ^[1] Azienda Policlinico Umberto 1-Sapienza University, Rome, Italy. breccia@bce.uniroma1.it. ^[2] Hematology, Nuovo Regina Margherita Hospital, Rome, Italy. ^[3] Hematology, Belcolle Hospital, Viterbo, Italy. ^[4] Hematology, S. Eugenio Hospital, Rome, Italy. ^[5] Tor Vergata University, Rome, Italy. ^[6] Hematology, S. Giovanni Hospital, Rome, Italy. ^[7] Hematology, S. Maria Goretti Hospital, Latina, Italy. ^[8] Azienda Policlinico Umberto 1-Sapienza University, Rome, Italy. ^[9] Hematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute, Rome, Italy. ^[10] Hematology, Fabrizio Spaziani Hospital, Frosinone, Italy. ^[11]

关键词 Myelofibrosis Outcome Response rate Ruxolitinib